Recipharm acquires Abbott's Spanish biopharmaceutical manufacturing

1 Oct 2010

Your browser does not support inline frames or is currently configured not to display inline frames.
Swedish company Recipharm AB has acquired Abbott’s
manufacturing site near Barcelona, Spain for an undisclosed sum.

The site, which will now be called Recipharm Parets SL, produces
solid dose, sterile ointments, oral liquids, aerosols and topical
products.

This move further enhances Recipharm’s capabilities, providing a
base in the strategically important Spanish market, whilst bringing
new customer relationships into the Recipharm Group. It also
reinforces Recipharm’s strategic goal to become one of the world’s
leading contract development and manufacturing organisations (CDMO),
offering a ‘one-stop shop’ for the development and manufacturing of
both small and large molecule biopharmaceuticals.

Recipharm will continue to produce all Abbott products currently
manufactured at the site. Recipharm says it also intends to retain
all existing employees.

Thomas Eldered, CEO of Recipharm, said: “We are extremely pleased
to be entering into another transaction with Abbott and to be
building on the successful integration of the Fontaine les Dijon
facility which we acquired last year from former Solvay
Pharmaceuticals. Both the facilities and staff are first class and
we look forward to nurturing and developing current and new business
in the important Spanish market”.

Recipharm AB is a contract development and manufacturing
organisation headquartered near Stockholm and with about 1950
employees. The Company operates several development and
manufacturing facilities in Sweden, France, the UK and Germany. It
supplies over six hundred products in multiple dosage forms that
include solid dose, granulates and powders, sterile liquids and
lyophilisates, semi solids, beta-lactams, hormones, and dry powder
inhalers. It also has biologics development capabilities.